Over-expression of RPL23 in myelodysplastic syndromes is associated with apoptosis resistance of CD34+ cells and predicts poor prognosis and distinct response to CHG chemotherapy or decitabine

Efficacy and safety of CHG regimen (low-dose cytarabine, homoharringtonine with G-CSF priming) as induction chemotherapy for elderly patients with high-risk MDS or AML transformed from MDS

(2011) Lingyun Wu et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

p53 Independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia

(2011) K P Ng et al.   LEUKEMIA

Relationship of differential gene expression profiles in CD34+ myelodysplastic syndrome marrow cells to disease subtype and progression

(2009) K. Sridhar et al.   BLOOD

Minimal diagnostic criteria for myelodysplastic syndromes and separation from ICUS and IDUS: update and open questions

(2009) P. Valent et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial

(2009) David P. Steensma et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome

(2009) Lingyun Wu et al.   LEUKEMIA & LYMPHOMA

How Common Are Extraribosomal Functions of Ribosomal Proteins?

(2009) Jonathan R. Warner et al.   MOLECULAR CELL

Myelodysplastic syndromes

(2008) S. D. Nimer   BLOOD

A ribosomal protein L23-nucleophosmin circuit coordinates Miz1 function with cell growth

(2008) Michael Wanzel et al.   NATURE CELL BIOLOGY